149 related articles for article (PubMed ID: 24616318)
1. Optic neuropathy and blindness associated with crizotinib for non-small-cell lung cancer with EML4-ALK translocation.
Chun SG; Iyengar P; Gerber DE; Hogan RN; Timmerman RD
J Clin Oncol; 2015 Feb; 33(5):e25-6. PubMed ID: 24616318
[No Abstract] [Full Text] [Related]
2. [Crizotinib: a targeted therapy in advanced ALK-positive non-small cell lung cancer].
Toffart AC; Sakhri L; Moro-Sibilot D
Rev Pneumol Clin; 2013 Apr; 69(2):111-6. PubMed ID: 23561899
[TBL] [Abstract][Full Text] [Related]
3. Long-term response to gefitinib and crizotinib in lung adenocarcinoma harboring both epidermal growth factor receptor mutation and EML4-ALK fusion gene.
Chiari R; Duranti S; Ludovini V; Bellezza G; Pireddu A; Minotti V; Bennati C; Crinò L
J Clin Oncol; 2014 Mar; 32(9):e30-2. PubMed ID: 24419120
[No Abstract] [Full Text] [Related]
4. Widespread renal polycystosis induced by crizotinib.
Di Girolamo M; Paris I; Carbonetti F; Onesti EC; Socciarelli F; Marchetti P
Tumori; 2015 Jul; 101(4):e128-31. PubMed ID: 25953441
[TBL] [Abstract][Full Text] [Related]
5. Responses to crizotinib in patients with ALK-positive lung adenocarcinoma who tested immunohistochemistry (IHC)-positive and fluorescence in situ hybridization (FISH)-negative.
Ma D; Wang Z; Yang L; Mu X; Wang Y; Zhao X; Li J; Lin D
Oncotarget; 2016 Sep; 7(39):64410-64420. PubMed ID: 27418132
[TBL] [Abstract][Full Text] [Related]
6. Severe acute interstitial lung disease after crizotinib therapy in a patient with EML4-ALK-positive non-small-cell lung cancer.
Tamiya A; Okamoto I; Miyazaki M; Shimizu S; Kitaichi M; Nakagawa K
J Clin Oncol; 2013 Jan; 31(1):e15-7. PubMed ID: 23169500
[No Abstract] [Full Text] [Related]
7. Successful crizotinib retreatment after crizotinib-induced interstitial lung disease.
Yanagisawa S; Inoue A; Koarai A; Ono M; Tamai T; Ichinose M
J Thorac Oncol; 2013 Aug; 8(8):e73-4. PubMed ID: 23857405
[No Abstract] [Full Text] [Related]
8. A new human lung adenocarcinoma cell line harboring the EML4-ALK fusion gene.
Isozaki H; Yasugi M; Takigawa N; Hotta K; Ichihara E; Taniguchi A; Toyooka S; Hashida S; Sendo T; Tanimoto M; Kiura K
Jpn J Clin Oncol; 2014 Oct; 44(10):963-8. PubMed ID: 25170107
[TBL] [Abstract][Full Text] [Related]
9. New insights into anaplastic lymphoma kinase-positive nonsmall cell lung cancer.
Dubey AP; Pathi N; Viswanath S; Rathore A; Pathak A; Sud R
Indian J Cancer; 2017; 54(1):203-208. PubMed ID: 29199691
[TBL] [Abstract][Full Text] [Related]
10. Acquired resistance to crizotinib in advanced lung adenocarcinoma with MET exon 14 skipping.
Zhang Y; Yin J; Peng F
Lung Cancer; 2017 Nov; 113():69-71. PubMed ID: 29110851
[No Abstract] [Full Text] [Related]
11. Disease flare after treatment discontinuation in a patient with EML4-ALK lung cancer and acquired resistance to crizotinib.
Pop O; Pirvu A; Toffart AC; Moro-Sibilot D
J Thorac Oncol; 2012 Aug; 7(8):e1-2. PubMed ID: 22797152
[No Abstract] [Full Text] [Related]
12. Efficacy and safety of crizotinib among Chinese EML4-ALK-positive, advanced-stage non-small cell lung cancer patients.
Cao Y; Xiao G; Qiu X; Ye S; Lin T
PLoS One; 2014; 9(12):e114008. PubMed ID: 25501361
[TBL] [Abstract][Full Text] [Related]
13. Alternate-day Treatment with Crizotinib for Drug-induced Esophagitis and Liver Damage in a Patient with EML4-ALK Fusion Gene-positive Lung Adenocarcinoma.
Tsukita Y; Fukuhara T; Kobayashi M; Morita M; Suzuki A; Watanabe K; Noguchi T; Kurata Y; Suno M; Maemondo M
Intern Med; 2015; 54(24):3185-8. PubMed ID: 26666609
[TBL] [Abstract][Full Text] [Related]
14. Durable brain response with pulse-dose crizotinib and ceritinib in ALK-positive non-small cell lung cancer compared with brain radiotherapy.
Dudnik E; Siegal T; Zach L; Allen AM; Flex D; Yust-Katz S; Limon D; Hirsch FR; Peled N
J Clin Neurosci; 2016 Apr; 26():46-9. PubMed ID: 26677785
[TBL] [Abstract][Full Text] [Related]
15. [Renal cysts - A novel complication of crizotinib treatment for lung cancer].
CsToth I; Meert AP; Sculier JP; Berghmans T
Rev Mal Respir; 2015 Nov; 32(9):956-8. PubMed ID: 26033699
[TBL] [Abstract][Full Text] [Related]
16. Adenocarcinoma of the lung with miliary brain and pulmonary metastases with echinoderm microtubule-associated protein like 4-anaplastic lymphoma kinase translocation treated with crizotinib: a case report.
Falk AT; Poudenx M; Otto J; Ghalloussi H; Barrière J
Lung Cancer; 2012 Dec; 78(3):282-4. PubMed ID: 22999080
[TBL] [Abstract][Full Text] [Related]
17. Lung adenocarcinoma with concurrent KRAS mutation and ALK rearrangement responding to crizotinib: case report.
Campos-Gomez S; Lara-Guerra H; Routbort MJ; Lu X; Simon GR
Int J Biol Markers; 2015 May; 30(2):e254-7. PubMed ID: 25588859
[TBL] [Abstract][Full Text] [Related]
18. A Case of Lung Adenocarcinoma Resistant to Crizotinib Harboring a Novel EML4-ALK Variant, Exon 6 of EML4 Fused to Exon 18 of ALK.
Anai S; Takeshita M; Ando N; Ikematsu Y; Mishima S; Ishida K; Inoue K
J Thorac Oncol; 2016 Oct; 11(10):e126-8. PubMed ID: 27663401
[No Abstract] [Full Text] [Related]
19. Clinical outcomes in ALK-rearranged lung adenocarcinomas according to ALK fusion variants.
Cha YJ; Kim HR; Shim HS
J Transl Med; 2016 Oct; 14(1):296. PubMed ID: 27756333
[TBL] [Abstract][Full Text] [Related]
20. ALK inhibitors in the treatment of advanced NSCLC.
Gridelli C; Peters S; Sgambato A; Casaluce F; Adjei AA; Ciardiello F
Cancer Treat Rev; 2014 Mar; 40(2):300-6. PubMed ID: 23931927
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]